Day Two Relief, Week Twelve Questions: A Phase Three Depression Trial Clears Its Bar
Download MP3Day Two Relief, Week Twelve Questions: A Phase Three Depression Trial Clears Its Bar
Helus Pharma reported its Phase 3 APPROACH trial of HLP003, an investigational deuterated psilocin added to an antidepressant, beat placebo by 7.6 MADRS points at week 6 in 222 adults with major depressive disorder; it is not approved and a second pivotal trial runs to late 2027.
Source
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder — GlobeNewswire / Helus Pharma, November 16, 2026
Join the Recovered Life Community here!
